

Orchard Therapeutics plc
245 Hammersmith Road
London W6 8PW
United Kingdom

August 17, 2023

Via EDGAR Transmission

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Orchard Therapeutics plc: Registration Statement on Form S-3, filed August 10, 2023 (File No. 333-273891)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “**Act**”), Orchard Therapeutics plc (the “**Company**”) hereby requests that the effective date of the above-referenced registration statement, as amended (the “**Registration Statement**”) be accelerated to August 21, 2023, at 4:01 p.m. Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.

If you have any questions regarding this request, please contact Catherine Magazu of Goodwin Procter LLP at (617) 570-8274.

Sincerely,
Orchard Therapeutics plc

/s/ Frank E. Thomas

Frank E. Thomas
President and Chief Operating Officer

cc: Bobby Gaspar, M.D., Ph.D., *Chief Executive Officer, Orchard Therapeutics plc*
Christopher York, *Corporate Counsel, Orchard Therapeutics plc*